After 84 weeks, tirzepatide participants lost an average of 26.6%, while those on the highest dose of retatrutide lost around 24.2% over 48 weeks
The pursuit of novel urate excretion agents has led to innovative approaches
Therefore, for all participating HOPDs, we estimate removal of this measure will decrease burden for voluntary reporting for the CY 2025 reporting period by approximately 1,719,380 hours for 51,581,411 patients (0.033 hours 206,325,645 patients 50 percent response rate 50 percent of HOPDs) at a savings of $44,067,709 (1,719,380 hours $25.63/hour)
NewSelf claims a 24-hour turnaround for prescription decisions, similar to TrimRx's speed
The body gradually adapts, and for most people, the severity decreases over time even as the dose increases
Available from: ideas/obesity-drugs-food-industry 24 Erman, M., 2023